Eutilex Co. Ltd., of Seoul, said it entered a strategic partnership with Zhejiang Huahai Pharmaceutical Ltd., of Shanghai, which will take a $30 million equity stake in Eutilex and in return receive an exclusive license to develop and commercialize EU-101, a humanized monoclonal antibody for cancer treatment, in the People's Republic of China, Taiwan, Hong Kong and Macau.